migraine
Novartis migraine prevention drug scores EU approval
July 31, 2018Manufacturing and Production, Sales and Marketing Aimovig, Europe, Novartis, migraine, pharma
Novartis is celebrating the news that its calcitonin gene-related peptide receptor (CGRP-R) pathway therapy Aimovig (erenumab) has been approved by …
Allergan’s atogepant fulfils primary endpoint in episodic migraine
June 12, 2018Manufacturing and Production, Research and Development Allergan, atogepant, migraine, pharma
Allergan has made ground in its quest to become “the headache company” with the release of new Phase 2b/3 data …
Amgen/Novartis potential blockbuster migraine med gets FDA nod
May 18, 2018Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical
The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …
Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form
May 16, 2018Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma
Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …
Allergan unveils second bout of Phase 3 success in migraine
April 30, 2018Research and Development, Sales and Marketing Allergan, migraine, pharma, ubrogepant
Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related …
Amgen and Novartis’ Aimovig shines in migraine at Phase 3
April 18, 2018Research and Development Aimovig, Amgen, Novartis, migraine, pharma
Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …
Reaction mixed to Biohaven’s migraine drug results
March 27, 2018Manufacturing and Production, Research and Development Allergan, Biohaven, CGRP, biotech, drugs, migraine, pharma, pharmaceutical
Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …
Insider Interview: Allergan’s R&D Chief on plans to be “the headache company”
February 22, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, David Nicholson, Insider Interview, migraine, pharma
Speaking to Pharmafocus , David Nicholson, Chief R&D Officer at Allergan, revealed that the company has big plans in the …
Novartis’ Phase 3 migraine data could revolutionise treatment
November 30, 2017Research and Development CGRP, Novartis Amgen, biotech, drugs, migraine, pharma, pharmaceutical
Descriptions of treatments as ‘revolutionary’ or ‘ground-breaking’ are ten a penny in the pharmaceutical industry, very rarely do such treatments …
Amgen boosted in race to market for migraine drug
November 17, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III
Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
Amgen, Novartis migraine drug meets primary endpoint in Phase II study
June 9, 2016Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine
A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …
Teva and Heptares enter $400m agreement for small-molecule migraine treatment
November 25, 2015Research and Development Heptares, Teva, collaboration, migraine
Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to …
Amgen and Novartis partner on Alzheimer’s and migraine treatments
September 2, 2015Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience
Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine. The companies plan …
Teva lifted by positive migraine drug results
May 15, 2015Sales and Marketing TEV-48125, Teva, headaches, migraine
Patients who take either dose of Teva’s investigational treatment for chronic migraine improve more than those taking a placebo according …
Allergan in $958m neurology deal
January 25, 2013Sales and Marketing Allergan, CNS, MAP Pharmaceuticals, migraine
Allergan is to pay $958m for MAP Pharmaceuticals in a deal which sees both companies hoping to reap the benefits …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
